MALAGOLA, MICHELE
 Distribuzione geografica
Continente #
NA - Nord America 20.743
AS - Asia 13.031
EU - Europa 9.731
SA - Sud America 2.626
AF - Africa 278
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 21
Totale 46.451
Nazione #
US - Stati Uniti d'America 20.333
SG - Singapore 4.613
CN - Cina 4.188
UA - Ucraina 2.364
BR - Brasile 2.152
IT - Italia 1.507
HK - Hong Kong 1.457
DE - Germania 1.390
VN - Vietnam 881
PL - Polonia 868
FI - Finlandia 807
FR - Francia 653
GB - Regno Unito 503
TR - Turchia 481
RU - Federazione Russa 465
BD - Bangladesh 402
IE - Irlanda 393
IN - India 368
SE - Svezia 297
CA - Canada 193
AR - Argentina 171
MX - Messico 125
IQ - Iraq 116
ZA - Sudafrica 98
NL - Olanda 94
EC - Ecuador 78
ES - Italia 75
ID - Indonesia 71
JP - Giappone 65
CZ - Repubblica Ceca 64
CO - Colombia 63
SA - Arabia Saudita 57
AT - Austria 54
VE - Venezuela 49
PK - Pakistan 46
BE - Belgio 45
UZ - Uzbekistan 45
PY - Paraguay 38
MA - Marocco 34
JO - Giordania 31
AE - Emirati Arabi Uniti 24
KE - Kenya 24
EG - Egitto 23
IL - Israele 23
JM - Giamaica 23
NG - Nigeria 23
CL - Cile 20
EU - Europa 20
PE - Perù 20
UY - Uruguay 20
AU - Australia 19
LT - Lituania 18
DZ - Algeria 17
MY - Malesia 16
DK - Danimarca 15
IR - Iran 14
MU - Mauritius 14
PT - Portogallo 14
TN - Tunisia 14
AZ - Azerbaigian 13
DO - Repubblica Dominicana 13
ET - Etiopia 13
GR - Grecia 13
PH - Filippine 13
TH - Thailandia 13
NP - Nepal 12
OM - Oman 12
CH - Svizzera 11
CR - Costa Rica 11
KZ - Kazakistan 11
BO - Bolivia 10
HN - Honduras 10
MD - Moldavia 10
PA - Panama 10
AL - Albania 9
BG - Bulgaria 9
KG - Kirghizistan 9
PS - Palestinian Territory 9
SN - Senegal 9
KR - Corea 8
BA - Bosnia-Erzegovina 7
RO - Romania 7
RS - Serbia 6
AM - Armenia 5
EE - Estonia 5
HU - Ungheria 5
LK - Sri Lanka 5
LV - Lettonia 5
TT - Trinidad e Tobago 5
HR - Croazia 4
KW - Kuwait 4
LB - Libano 4
NI - Nicaragua 4
SK - Slovacchia (Repubblica Slovacca) 4
SV - El Salvador 4
BB - Barbados 3
CI - Costa d'Avorio 3
CU - Cuba 3
GT - Guatemala 3
GY - Guiana 3
Totale 46.412
Città #
Singapore 2.347
Woodbridge 2.001
Ashburn 1.655
Jacksonville 1.616
Fairfield 1.565
Hong Kong 1.451
Houston 1.347
Ann Arbor 1.125
San Jose 1.014
Warsaw 848
The Dalles 776
Princeton 736
Cambridge 734
Wilmington 730
Beijing 673
Seattle 636
Chandler 629
New York 572
Nanjing 539
Helsinki 412
Lauterbourg 389
Dublin 387
Los Angeles 386
Istanbul 352
Dallas 301
Ho Chi Minh City 279
Munich 271
Des Moines 256
Brescia 250
Nanchang 233
São Paulo 205
Hanoi 186
Milan 176
Buffalo 167
Changsha 150
Moscow 149
Redondo Beach 143
Shanghai 134
Tianjin 131
Jinan 129
Shenyang 123
Hebei 118
San Francisco 115
Dearborn 110
San Diego 108
Council Bluffs 106
Santa Clara 104
Boardman 90
Chicago 90
Turku 89
Orem 88
Hangzhou 87
Jiaxing 86
Rome 78
London 73
Brooklyn 67
Kunming 67
Kocaeli 64
Nuremberg 61
Frankfurt am Main 60
Guangzhou 58
Verona 58
Denver 57
Rio de Janeiro 56
Ningbo 55
Tokyo 55
Toronto 54
Brasília 53
Chennai 53
Zhengzhou 53
Johannesburg 51
Brno 50
Regensburg 50
Phoenix 47
Belo Horizonte 46
Brussels 45
Montreal 45
Atlanta 44
Curitiba 44
Mexico City 44
Pune 43
Boston 42
Baghdad 39
Da Nang 39
Tashkent 39
Stockholm 36
Lanzhou 35
Biên Hòa 34
Amsterdam 33
Manchester 31
Charlotte 30
Mumbai 30
Taizhou 30
Poplar 29
Paris 28
Amman 27
Haikou 27
Norwalk 27
Porto Alegre 27
Guayaquil 26
Totale 29.534
Nome #
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 326
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis 317
BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE 295
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients 293
Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation 271
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 239
Zebrafish disease models in hematology: Highlights on biological and translational impact 236
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 210
A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation 209
Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria 203
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 198
Betaherpesvirus Reactivation and Toll-Like Receptor Expression After Allogeneic Stem Cell Transplantation. 190
Targeting HRASV12G Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway. 188
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 186
EXPRESSION OF TOLL-LIKE RECEPTORS ON PERIPHERAL BLOOD CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ONGOING RESULTS OF A PROSPECTIVE STUDY. 184
A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs) 180
Profile of Toll-Like Receptors on Peripheral Blood Cells in Relation to Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation 178
Advances in CMV Management: A Single Center Real-Life Experience 177
Acute graft-versus-host disease and expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation 174
Central Venous Catheter-Related Bloodstream Infection Caused by Brevibacterium casei in a Hematology Patient 172
TARGETING HRASV12G EXPRESSION TO THE ZEBRAFISH EARLY HEMOGENIC PROGENITORS INDUCES A MYELOPROLIFERATIVE DISORDER BY REPRESSING THE NOTCH PATHWAY. 171
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 170
Expression of Toll-Like Receptors on Peripheral Blood Cells After Allogeneic Stem Cell Transplantation: Results of a Prospective Study. 169
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 169
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 168
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome 167
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 165
Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence? 164
Chitosan-Hydrogel Polymeric Scaffold Acts as an Independent Primary Inducer of Osteogenic Differentiation in Human Mesenchymal Stromal Cells 164
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS 162
Low dose AraC for Myelodysplastic Syndromes: is it still a current therapy ?. 160
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 160
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 160
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 158
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 157
Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. 156
MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT. 155
5-azacitidine five days/monthly schedule in symptomatic low-risk (IPSS: 0-1) myelodisplastic (MDS) patients. clinical and biological effects. 154
Central nervous system angiitis in Hodgkin's disease. 154
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 154
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 153
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 152
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 152
PARAMETERS OF PROTEIN METABOLISM AND THYROID FUNCTION AS PREDICTORS OF A SCORING SYSTEM FOR ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE 152
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 152
Ethical and legal issues in haematopoietic stem cells (HSC) donation: the controversial and problematic aspects in minors 152
Targeting oncogene expression to endothelial cells induces proliferation of the myelo-erythroid lineage by repressing the notch pathway. 151
Development of a cell culture model based on biocompatible polymeric scaffolds engineered with human Mesenchymal Stromal Cells (MSCs) for cartilage and bone regenerative therapy 151
Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation. 150
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 150
Single Cell Analysis of Circulating Endothelial Cells in Allogeneic Hematopoietic Stem Cell Transplant; To Whom Do They Belong: Host or Donor? 149
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial 148
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 148
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 147
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 146
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent 145
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing 145
ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience 144
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 143
Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives 142
A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY: THE PYROSEQUENCING 141
Digital PCR (Dpcr) a Step Forward to Detection and Quantification of Minimal Residual Disease (MRD) in Ph+/BCR-ABL1 Chronic Myeloid Leukemia (CML) 141
Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. 140
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 140
Advances in the treatment of monoclonal gammapathies: the emerging role of targeted therapy in plasma cell dyscrasias. 139
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 138
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 138
Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients 138
Is the New Tci Score Sufficient to Categorize the Intensity of Conditioning? a Single-Centre Study 136
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia 136
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 136
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-kit positive acute myeloid leukemia. Results of an italian multicentric phase II study. 136
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 135
Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease. 135
Index of Bone Marrow Output and Imbalance of B-Lymphocyte Homeostasis before and after Transplantation Correlate Differently with Graft-Versus-Host Disease and Relapse 135
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 135
AIDA: The italian way of treating acute promyelocytic leukemia (APL): final act . 135
Successful hematopoietic stem cell transplantation for complete CTLA-4 haploinsufficiency due to a de novo monoallelic 2q33.2-2q33.3 deletion 135
Acute myeloid leukemia in the elderly: results obtained with conventional chemotherapy 133
Expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation: ongoing results of a prospective study. 131
ANTI-CMV IMMUNOGLOBULINS IN ASSOCIATION WITH ANTI-CMV DRUGS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES SUBMITTED TO ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTI-CENTRE RETROSPECTIVE EXPERIENCE 131
Allogeneic transplantation for patient with myelodisplastic sindromes: a single centre experience 131
IN VIVO STUDY (MYCEC0617) OF CD34+-HSC AND CEC MUTATIONAL PROFILE FOR INVESTIGATING CELL ORIGIN AND PATHOGENESIS OF PRIMARY MYELOFIBROSIS (PMF) 131
PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA 130
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 130
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 130
ACHIEVEMENT OF COMPLETE REMISSION WITH PONATINIB THERAPY FOR PHILADELPHIA ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE REPORT. 130
Urinary Protein Levels in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Predict Severe Disease Related Complications at Myeloma Progression 130
Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case? 130
Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia 129
Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. 129
Four Drugs combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as induction therapy for newly diagnosed acute myeloid leukemia patients younger than 65 yrs: response and follow up of 127 patients. 129
P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY 128
Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. 128
DIGITAL PCR IN PH plus CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION 128
Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation 128
Long term outcome of ph+ cml patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. 127
Safety and Efficacy of ATG-based GvHD prophylaxis in allogeneic stem cell transplantation for acute leukemia and myelodysplastic syndrome: a single center experience 127
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Level. Comparison of Qpcr, d-PCR and CD26 Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) 127
Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection 127
Totale 15.948
Categoria #
all - tutte 229.998
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 229.998


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021180 0 0 0 0 0 0 0 0 0 0 0 180
2021/20222.684 121 460 55 130 111 203 128 194 141 365 203 573
2022/20232.153 435 45 53 175 162 597 7 199 259 30 91 100
2023/20242.723 125 72 190 140 130 457 122 93 758 32 40 564
2024/20256.853 62 79 68 775 775 559 640 200 896 446 1.300 1.053
2025/202615.693 1.265 2.060 1.266 2.309 1.273 1.189 2.310 699 979 1.356 600 387
Totale 47.492